Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | The benefits of improving tumor cell quantification in CTCL

Maarten Vermeer • 15 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Antibodies Mogamulizumab

Maarten Vermeer, MD, PhD, Leiden University Medical Center, Leiden, Netherlands, outlines unmet needs in cutaneous T-cell lymphoma, highlighting challenges around the quantification of tumor cells in CTCL, due to heterogeneity in cell surface markers both between and within individual patients. Dr Vermeer also comments on how improving tumor cell quantification could be used to enhance therapeutic approaches such as extracorporeal photopheresis and mogamulizumab. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Maarten Vermeer

1:01
Measuring CTCs in CTCL
Maarten Vermeer • 15 Oct 2021
0:55
Multimarker approach to CTC analysis in CTCL
Maarten Vermeer • 15 Oct 2021
1:10
Unmet needs for late-stage CTCL
Maarten Vermeer • 15 Oct 2021
1:04
Unmet needs in early-stage mycosis fungoides
Maarten Vermeer • 15 Oct 2021

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals